Details of Disease

General Information of Disease (ID: DISSL43L)

Disease Name	Metastatic melanoma
Synonyms	metastatic melanoma; metastatic malignant melanoma
Disease Class	2D50-2E2Z: Metastatic tumour
Definition	A melanoma that has spread from its primary site to another anatomic site. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.
Disease Hierarchy	DIS1RRCY: Melanoma DISSL43L: Metastatic melanoma
ICD Code	ICD-11 ICD-11: 2E2Z ICD-10 ICD-10: C76-C80
Disease Identifiers	MONDO ID MONDO_0005191 UMLS CUI C0278883 MedGen ID 83002

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Trametinib	DM2JGQ3	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RG6180	DMVE8CN	Phase 2	NA	[2]
UV1 vaccine	DM9MM7V	Phase 2	Vaccine	[3]
IN10018	DMPXOVA	Phase 1	Small molecular drug	[4]
PRAME antigen-specific cancer immunotherapeutic	DMXRJ1N	Phase 1	NA	[5]
SER-401	DME7B2O	Phase 1	Live biotherapeutic product	[6]
TTC-352	DM7CHZ2	Phase 1	NA	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 51 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BIRC7	TTHZ8TA	Limited	Altered Expression	[8]
CD160	TTOFEAS	Limited	Altered Expression	[9]
CD248	TTYJWT7	Limited	Biomarker	[10]
CD58	TT5KSBY	Limited	Biomarker	[11]
CSPG4	TT7MYXI	Limited	Biomarker	[12]
CYSLTR2	TT0PZR5	Limited	Genetic Variation	[13]
FPR1	TT5Y4EM	Limited	Biomarker	[14]
GNAQ	TTL1SRG	Limited	Genetic Variation	[15]
HRH4	TTXJ178	Limited	Biomarker	[16]
ITGA1	TTPERWV	Limited	Biomarker	[17]
ITGAE	TTH0Z37	Limited	Altered Expression	[17]
MAGEC2	TTKGUEB	Limited	Biomarker	[18]
MAP2K1	TTIDAPM	Limited	Biomarker	[19]
NCR1	TTQNRJM	Limited	Biomarker	[20]
NT5E	TTK0O6Y	Limited	Biomarker	[21]
NUAK1	TT65FL0	Limited	Biomarker	[22]
OSMR	TTAH0KM	Limited	Biomarker	[23]
PTK7	TTXH2ZN	Limited	Biomarker	[24]
RAPGEF3	TTOE7I0	Limited	Genetic Variation	[25]
RAPGEF4	TTOS63B	Limited	Genetic Variation	[25]
TAP1	TT7JZI8	Limited	Altered Expression	[26]
F2R	TTL935N	Disputed	Biomarker	[27]
SRPK1	TTU3WV6	moderate	Biomarker	[28]
CDC7	TTSMTDI	Strong	Biomarker	[29]
CDK6	TTO0FDJ	Strong	Altered Expression	[30]
EPHA4	TTG84D3	Strong	Biomarker	[31]
GOT1	TTU507L	Strong	Biomarker	[32]
GPR18	TTSLJAR	Strong	Biomarker	[33]
IL24	TT1EPXZ	Strong	Altered Expression	[34]
KIT	TTX41N9	Strong	Genetic Variation	[35]
LGALS3	TTFPQV7	Strong	Biomarker	[36]
M6PR	TT95ICL	Strong	Altered Expression	[37]
MAGEA3	TTWSKHD	Strong	Altered Expression	[38]
MAP2K2	TT8H9GB	Strong	Biomarker	[19]
MAP3K9	TTUNSIX	Strong	Genetic Variation	[39]
MC1R	TT0MV2T	Strong	Biomarker	[40]
MCAM	TTHRE05	Strong	Biomarker	[41]
MELTF	TT8OBT3	Strong	Biomarker	[42]
MGMT	TTJ8DV7	Strong	Posttranslational Modification	[43]
MIA	TT5HNVS	Strong	Biomarker	[44]
MLANA	TT362RB	Strong	Biomarker	[45]
NRAS	TTW2R9X	Strong	Genetic Variation	[46]
PDCD1	TTNBFWK	Strong	Biomarker	[47]
PDK3	TTDEQIP	Strong	Biomarker	[48]
PLEKHA5	TTCDZMO	Strong	Biomarker	[49]
PMEL	TT8MK59	Strong	Biomarker	[50]
PRKD1	TTSLUMT	Strong	Biomarker	[51]
RAB22A	TTAJ746	Strong	Altered Expression	[52]
S100B	TTQ0V86	Strong	Biomarker	[53]
NLRP1	TTQX29T	Definitive	Biomarker	[54]
TYR	TTULVH8	Definitive	Altered Expression	[55]
------------------------------------------------------------------------------------


⏷ Show the Full List of 51 DTT(s)

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC45A2	DTNCJAT	moderate	Posttranslational Modification	[56]
ABCB5	DTKVEXO	Strong	Altered Expression	[57]
------------------------------------------------------------------------------------

This Disease Is Related to 67 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAR	OTQNOHR8	Limited	Altered Expression	[58]
ADGRG1	OTQBB8NT	Limited	Biomarker	[59]
AHNAK	OT6KH1WG	Limited	Genetic Variation	[60]
AMIGO2	OTPAIT1O	Limited	Biomarker	[24]
CANX	OTYP1F6J	Limited	Biomarker	[61]
CD2AP	OTC76KQM	Limited	Biomarker	[62]
DDX11	OT1WR3MD	Limited	Altered Expression	[63]
DEGS1	OT4WXPKW	Limited	Biomarker	[64]
DESI1	OTFNIW98	Limited	Biomarker	[65]
EBF3	OTB0IWLW	Limited	Altered Expression	[66]
EIF1AX	OTWG2LAB	Limited	Genetic Variation	[13]
ESRP1	OTNCS4SL	Limited	Posttranslational Modification	[67]
EYA1	OTHU807A	Limited	Altered Expression	[68]
FOXD3	OTXYV6GO	Limited	Biomarker	[69]
FUT2	OTLXM6WI	Limited	Biomarker	[70]
FUT8	OTJJCVG1	Limited	Altered Expression	[70]
IFI30	OT9DERT1	Limited	Altered Expression	[71]
IGSF8	OTU22IKI	Limited	Biomarker	[72]
INTU	OTXB13E6	Limited	Genetic Variation	[73]
ITGA9	OTHN1IKA	Limited	Altered Expression	[74]
MAP2	OT6UYT3X	Limited	Biomarker	[75]
MRI1	OTOP49DM	Limited	Altered Expression	[76]
NBL1	OTT37U4O	Limited	Biomarker	[77]
NFATC2	OTK5T6HZ	Limited	Biomarker	[78]
PEG10	OTWD2278	Limited	Biomarker	[79]
PIWIL3	OTQ1B8R4	Limited	Altered Expression	[80]
PPP6C	OTR1STMJ	Limited	Genetic Variation	[81]
RAB5B	OT06PN42	Limited	Altered Expression	[82]
RNF123	OTL59S8J	Limited	Altered Expression	[83]
SETMAR	OTE2MIMZ	Limited	Biomarker	[79]
SLC35G1	OTKZUA8O	Limited	Biomarker	[65]
TFG	OT2KJENI	Limited	Genetic Variation	[84]
TM9SF4	OT85D4H9	Limited	Altered Expression	[85]
MITF	OT6XJCZH	Disputed	Altered Expression	[86]
CRYBG1	OTIPDI15	moderate	Posttranslational Modification	[56]
RASSF6	OT25GVWY	moderate	Posttranslational Modification	[87]
SDCBP	OTS3NCC5	moderate	Biomarker	[27]
TRIB2	OTHSX3MX	moderate	Altered Expression	[88]
AKAP12	OTCVRDDX	Strong	Biomarker	[89]
ALDH1A3	OT1C9NKQ	Strong	Altered Expression	[90]
APAF1	OTJWIVY0	Strong	Genetic Variation	[91]
ATF1	OT251CI0	Strong	Biomarker	[92]
ETFA	OTXX61VZ	Strong	Biomarker	[93]
GOLGA4	OTCMEHNJ	Strong	Genetic Variation	[94]
GPC6	OTNJBESF	Strong	Altered Expression	[95]
HLA-DOA	OTZE5Q7R	Strong	Biomarker	[96]
IGF2BP1	OT9G360P	Strong	Altered Expression	[97]
IL4I1	OTK54C63	Strong	Biomarker	[98]
MED23	OTKZQT0R	Strong	Altered Expression	[99]
MX1	OT6X8G5T	Strong	Genetic Variation	[100]
PAX3	OTN5PJZV	Strong	Biomarker	[71]
PHIP	OTZY806Z	Strong	Biomarker	[101]
PHLDA1	OTFTWMIQ	Strong	Altered Expression	[102]
PKP1	OT9HSQ8F	Strong	Altered Expression	[103]
PLXNC1	OTJ5XKYY	Strong	Biomarker	[104]
RAB8A	OTPB54Y3	Strong	Biomarker	[105]
RPRD1A	OTXTV6FU	Strong	Biomarker	[106]
RTL1	OTOT33IM	Strong	Biomarker	[107]
S100A1	OT1F2G4J	Strong	Genetic Variation	[108]
SEMA3E	OTD4S36H	Strong	Altered Expression	[109]
SOX10	OTF25ULQ	Strong	Biomarker	[110]
STK11	OT1YZSP3	Strong	Biomarker	[111]
STPG4	OT5K4UFL	Strong	Altered Expression	[32]
TMEM31	OTKDPZD4	Strong	Altered Expression	[112]
LYPLA1	OTENU47T	Definitive	Altered Expression	[26]
PHLPP1	OTIFXW8D	Definitive	Biomarker	[113]
SCD5	OTSSUQ3Z	Definitive	Altered Expression	[55]
------------------------------------------------------------------------------------


⏷ Show the Full List of 67 DOT(s)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Clinical pipeline report, company report or official report of Roche.
3	ClinicalTrials.gov (NCT04382664) UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT04109456) IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma. U.S. National Institutes of Health.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline.
6	ClinicalTrials.gov (NCT03817125) Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW). U.S. National Institutes of Health.
7	ClinicalTrials.gov (NCT03201913) Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy. U.S. National Institutes of Health.
8	Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine.Int J Cancer. 2005 Dec 20;117(6):1032-8. doi: 10.1002/ijc.21267.
9	Human hemokinin-1 promotes migration of melanoma cells and increases MMP-2 and MT1-MMP expression by activating tumor cell NK1 receptors.Peptides. 2016 Sep;83:8-15. doi: 10.1016/j.peptides.2016.07.004. Epub 2016 Jul 22.
10	A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.Invest New Drugs. 2018 Feb;36(1):103-113. doi: 10.1007/s10637-017-0530-4. Epub 2017 Nov 11.
11	Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors.Hum Gene Ther. 2006 Feb;17(2):239-44. doi: 10.1089/hum.2006.17.239.
12	Multi-omics Analysis of Serum Samples Demonstrates Reprogramming of Organ Functions Via Systemic Calcium Mobilization and Platelet Activation in Metastatic Melanoma.Mol Cell Proteomics. 2017 Jan;16(1):86-99. doi: 10.1074/mcp.M116.063313. Epub 2016 Nov 22.
13	Intraventricular melanocytoma diagnosis confirmed by gene mutation profile.Neuropathology. 2018 Jun;38(3):288-292. doi: 10.1111/neup.12443. Epub 2017 Dec 11.
14	Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.J Exp Clin Cancer Res. 2017 Dec 8;36(1):180. doi: 10.1186/s13046-017-0650-x.
15	Intermediate-grade meningeal melanocytoma associated with nevus of Ota: a case report and review of the literature.Melanoma Res. 2015 Aug;25(4):273-8. doi: 10.1097/CMR.0000000000000163.
16	Histamine therapeutic efficacy in metastatic melanoma: Role of histamine H4 receptor agonists and opportunity for combination with radiation.Oncotarget. 2017 Apr 18;8(16):26471-26491. doi: 10.18632/oncotarget.15594.
17	Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma.Oncoimmunology. 2018 Aug 6;7(10):e1490855. doi: 10.1080/2162402X.2018.1490855. eCollection 2018.
18	Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.PLoS One. 2011;6(6):e21418. doi: 10.1371/journal.pone.0021418. Epub 2011 Jun 27.
19	Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity.J Neurosurg. 2019 Nov 1;133(6):1704-1709. doi: 10.3171/2019.8.JNS19643.
20	NK cell heparanase controls tumor invasion and immune surveillance.J Clin Invest. 2017 Jun 30;127(7):2777-2788. doi: 10.1172/JCI92958. Epub 2017 Jun 5.
21	The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.Tumour Biol. 2019 Apr;42(4):1010428319837138. doi: 10.1177/1010428319837138.
22	Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1.J Invest Dermatol. 2014 Feb;134(2):441-451. doi: 10.1038/jid.2013.340. Epub 2013 Aug 9.
23	Loss of oncostatin M receptor beta in metastatic melanoma cells.Oncogene. 2007 Feb 8;26(6):881-92. doi: 10.1038/sj.onc.1209844. Epub 2006 Aug 7.
24	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.Mol Cell. 2017 Nov 16;68(4):731-744.e9. doi: 10.1016/j.molcel.2017.11.004.
25	EPAC-RAP1 Axis-Mediated Switch in the Response of Primary and Metastatic Melanoma to Cyclic AMP.Mol Cancer Res. 2017 Dec;15(12):1792-1802. doi: 10.1158/1541-7786.MCR-17-0067. Epub 2017 Aug 29.
26	Wnt5a signaling induced phosphorylation increases APT1 activity and promotes melanoma metastatic behavior.Elife. 2018 Apr 12;7:e34362. doi: 10.7554/eLife.34362.
27	MDA-9/syntenin is essential for factor VIIa-induced signaling, migration, and metastasis in melanoma cells.J Biol Chem. 2015 Feb 6;290(6):3333-48. doi: 10.1074/jbc.M114.606913. Epub 2014 Dec 10.
28	Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.Br J Cancer. 2014 Jul 29;111(3):477-85. doi: 10.1038/bjc.2014.342. Epub 2014 Jul 10.
29	Targeting CDC7 sensitizes resistance melanoma cells to BRAF(V600E)-specific inhibitor by blocking the CDC7/MCM2-7 pathway.Sci Rep. 2019 Oct 2;9(1):14197. doi: 10.1038/s41598-019-50732-w.
30	MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in MetastaticMelanoma.J Invest Dermatol. 2017 Sep;137(9):1955-1964. doi: 10.1016/j.jid.2017.03.039. Epub 2017 May 16.
31	Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma.Int J Cancer. 1997 Jun 11;71(6):1061-5. doi: 10.1002/(sici)1097-0215(19970611)71:6<1061::aid-ijc24>3.0.co;2-f.
32	Inhibition of glutamate oxaloacetate transaminase 1 in cancer cell lines results in altered metabolism with increased dependency of glucose.BMC Cancer. 2018 May 11;18(1):559. doi: 10.1186/s12885-018-4443-1.
33	Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target.Pigment Cell Melanoma Res. 2011 Feb;24(1):207-18. doi: 10.1111/j.1755-148X.2010.00781.x. Epub 2010 Oct 21.
34	IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.Melanoma Res. 2011 Feb;21(1):44-56. doi: 10.1097/CMR.0b013e3283382155.
35	Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report.Medicine (Baltimore). 2019 Nov;98(44):e17769. doi: 10.1097/MD.0000000000017769.
36	Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.Oncoimmunology. 2018 Mar 13;7(7):e1440930. doi: 10.1080/2162402X.2018.1440930. eCollection 2018.
37	BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.Clin Cancer Res. 2019 May 1;25(9):2783-2794. doi: 10.1158/1078-0432.CCR-18-2725. Epub 2019 Feb 14.
38	A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.J Immunol. 2003 Jul 1;171(1):219-25. doi: 10.4049/jimmunol.171.1.219.
39	Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.Nat Genet. 2011 Dec 25;44(2):165-9. doi: 10.1038/ng.1041.
40	Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting.Mol Pharm. 2019 Apr 1;16(4):1694-1702. doi: 10.1021/acs.molpharmaceut.9b00025. Epub 2019 Feb 25.
41	Gene electrotransfer of siRNAs against CD146 inhibits migration and invasion of human malignant melanoma cells SK-MEL28.Cancer Gene Ther. 2013 Mar;20(3):208-10. doi: 10.1038/cgt.2013.3. Epub 2013 Feb 1.
42	Inhibition of melanoma brain metastasis by targeting melanotransferrin at the cell surface.Pigment Cell Melanoma Res. 2009 Feb;22(1):86-98. doi: 10.1111/j.1755-148X.2008.00525.x. Epub 2008 Dec 1.
43	Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.Oncol Rep. 2012 Aug;28(2):654-8. doi: 10.3892/or.2012.1826. Epub 2012 May 18.
44	Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.Anticancer Res. 2017 Sep;37(9):5033-5037. doi: 10.21873/anticanres.11918.
45	Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: An effective first-line test for the workup of sentinel lymph node specimen.J Cutan Pathol. 2019 Apr;46(4):261-266. doi: 10.1111/cup.13412. Epub 2019 Jan 31.
46	Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.Acta Derm Venereol. 2019 Feb 1;99(2):206-210. doi: 10.2340/00015555-3080.
47	Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma.Front Oncol. 2019 Feb 14;9:84. doi: 10.3389/fonc.2019.00084. eCollection 2019.
48	Inactivation of the HIF-1/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity o... Cancer Res. 2012 Oct 1;72(19):5035-47.
49	PLEKHA5 regulates tumor growth in metastatic melanoma.Cancer. 2020 Mar 1;126(5):1016-1030. doi: 10.1002/cncr.32611. Epub 2019 Nov 26.
50	Effective oral delivery of gp100 plasmid vaccine against metastatic melanoma through multi-faceted blending-by-blending nanogels.Nanomedicine. 2019 Nov;22:102114. doi: 10.1016/j.nano.2019.102114. Epub 2019 Oct 23.
51	Protein kinase C inhibitor G6976 but not G6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: identification of the role of protein kinase D1.BMC Cancer. 2017 Jan 5;17(1):12. doi: 10.1186/s12885-016-3007-5.
52	RAB22A overexpression promotes the tumor growth of melanoma. Oncotarget. 2016 Nov 1;7(44):71744-71753.
53	Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy.Eur J Radiol. 2019 Dec;121:108688. doi: 10.1016/j.ejrad.2019.108688. Epub 2019 Oct 22.
54	Inhibition of ER stress-related IRE1/CREB/NLRP1 pathway promotes the apoptosis of human chronic myelogenous leukemia cell.Mol Immunol. 2018 Sep;101:377-385. doi: 10.1016/j.molimm.2018.07.002. Epub 2018 Jul 26.
55	SCD5 restored expression favors differentiation and epithelial-mesenchymal reversion in advanced melanoma.Oncotarget. 2018 Jan 9;9(7):7567-7581. doi: 10.18632/oncotarget.24085. eCollection 2018 Jan 26.
56	AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome.J Invest Dermatol. 2012 Jun;132(6):1689-97. doi: 10.1038/jid.2012.36. Epub 2012 Mar 8.
57	The influence of nano-TiO2 on metabolic activity, cytotoxicity and ABCB5 mRNA expression in WM-266-4 human metastatic melanoma cell line.J BUON. 2019 Jan-Feb;24(1):338-346.
58	ADAR1-mediated regulation of melanoma invasion.Nat Commun. 2018 May 31;9(1):2154. doi: 10.1038/s41467-018-04600-2.
59	The Adhesion G-Protein-Coupled Receptor, GPR56/ADGRG1, Inhibits Cell-Extracellular Matrix Signaling to Prevent Metastatic Melanoma Growth.Front Oncol. 2018 Feb 1;8:8. doi: 10.3389/fonc.2018.00008. eCollection 2018.
60	AHNAK is downregulated in melanoma, predicts poor outcome, and may be required for the expression of functional cadherin-1.Melanoma Res. 2016 Apr;26(2):108-16. doi: 10.1097/CMR.0000000000000228.
61	Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma.Cancer Lett. 2004 Jan 20;203(2):225-31. doi: 10.1016/j.canlet.2003.09.036.
62	Cysteine Proteases from V. cundinamarcensis (C. candamarcensis) Inhibit Melanoma Metastasis and Modulate Expression of Proteins Related to Proliferation, Migration and Differentiation.Int J Mol Sci. 2018 Sep 20;19(10):2846. doi: 10.3390/ijms19102846.
63	The DEAD/DEAH box helicase, DDX11, is essential for the survival of advanced melanomas.Mol Cancer. 2012 Nov 1;11:82. doi: 10.1186/1476-4598-11-82.
64	The roles of Galectin-3 in autoimmunity and tumor progression.Immunol Res. 2012 Apr;52(1-2):100-10. doi: 10.1007/s12026-012-8286-6.
65	Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.Melanoma Res. 2018 Feb;28(1):56-60. doi: 10.1097/CMR.0000000000000394.
66	Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.Oncotarget. 2017 Jan 24;8(4):6085-6101. doi: 10.18632/oncotarget.14042.
67	Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome.Pigment Cell Melanoma Res. 2015 Jan;28(1):82-93. doi: 10.1111/pcmr.12307. Epub 2014 Sep 30.
68	Eyes absent gene (EYA1) is a pathogenic driver and a therapeutic target for melanoma.Oncotarget. 2017 Sep 27;8(62):105081-105092. doi: 10.18632/oncotarget.21352. eCollection 2017 Dec 1.
69	FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma.Mol Cancer Res. 2014 Sep;12(9):1314-23. doi: 10.1158/1541-7786.MCR-14-0170. Epub 2014 Jul 24.
70	A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis.Cancer Cell. 2017 Jun 12;31(6):804-819.e7. doi: 10.1016/j.ccell.2017.05.007.
71	Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells.J Cell Biochem. 2018 Feb;119(2):2212-2221. doi: 10.1002/jcb.26383. Epub 2017 Oct 18.
72	EWI-2 negatively regulates TGF- signaling leading to altered melanoma growth and metastasis.Cell Res. 2015 Mar;25(3):370-85. doi: 10.1038/cr.2015.17. Epub 2015 Feb 6.
73	Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.Tumori. 2016 Oct 13;102(5):501-507. doi: 10.5301/tj.5000539. Epub 2016 Jul 27.
74	MicroRNA-125b suppresses the epithelial-mesenchymal transition and cell invasion by targeting ITGA9 in melanoma.Tumour Biol. 2016 May;37(5):5941-9. doi: 10.1007/s13277-015-4409-8. Epub 2015 Nov 23.
75	Increased expression of MAP2 inhibits melanoma cell proliferation, invasion and tumor growth in vitro and in vivo.Exp Dermatol. 2010 Nov;19(11):958-64. doi: 10.1111/j.1600-0625.2009.01020.x.
76	Structure of mediator of RhoA-dependent invasion (MRDI) explains its dual function as a metabolic enzyme and a mediator of cell invasion.Biochemistry. 2013 Aug 20;52(33):5675-84. doi: 10.1021/bi400556e. Epub 2013 Jul 31.
77	DAN (NBL1) promotes collective neural crest migration by restraining uncontrolled invasion.J Cell Biol. 2017 Oct 2;216(10):3339-3354. doi: 10.1083/jcb.201612169. Epub 2017 Aug 15.
78	NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis.Cancer Res. 2016 Jun 1;76(11):3145-55. doi: 10.1158/0008-5472.CAN-15-2511. Epub 2016 Mar 24.
79	Three-way and two-way rearrangements involving chromosomes 10, 2, 5 and 5, 2 in two marker chromosomes of a human melanoma cell line.Melanoma Res. 1994 Aug;4(4):259-65. doi: 10.1097/00008390-199408000-00008.
80	Expression of PIWIL3 in primary and metastatic melanoma.J Cancer Res Clin Oncol. 2017 Mar;143(3):433-437. doi: 10.1007/s00432-016-2305-2. Epub 2016 Nov 17.
81	PP6C hotspot mutations in melanoma display sensitivity to Aurora kinase inhibition.Mol Cancer Res. 2014 Mar;12(3):433-9. doi: 10.1158/1541-7786.MCR-13-0422. Epub 2013 Dec 12.
82	Gene expression patterns in melanocytic cells: candidate markers for early stage and malignant transformation.J Pathol. 2002 Jan;196(1):51-8. doi: 10.1002/path.1017.
83	Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-B Pathway in Melanoma.Clin Cancer Res. 2017 Aug 15;23(16):4831-4842. doi: 10.1158/1078-0432.CCR-17-0146. Epub 2017 Apr 7.
84	Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene.Genes Chromosomes Cancer. 2012 May;51(5):452-61. doi: 10.1002/gcc.21932. Epub 2012 Jan 17.
85	Human TM9SF4 Is a New Gene Down-Regulated by Hypoxia and Involved in Cell Adhesion of Leukemic Cells.PLoS One. 2015 May 11;10(5):e0126968. doi: 10.1371/journal.pone.0126968. eCollection 2015.
86	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma.Cell Rep. 2019 Jun 18;27(12):3573-3586.e7. doi: 10.1016/j.celrep.2019.05.069.
87	RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.Epigenetics. 2014 Nov;9(11):1496-503. doi: 10.4161/15592294.2014.983361.
88	TRIB2 as a biomarker for diagnosis and progression of melanoma.Carcinogenesis. 2015 Apr;36(4):469-77. doi: 10.1093/carcin/bgv002. Epub 2015 Jan 13.
89	SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk.Oncotarget. 2018 Sep 11;9(71):33515-33527. doi: 10.18632/oncotarget.26067. eCollection 2018 Sep 11.
90	Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes.Chem Biol Interact. 2019 Dec 1;314:108822. doi: 10.1016/j.cbi.2019.108822. Epub 2019 Sep 30.
91	Reduced Apaf-1 expression in human cutaneous melanomas.Br J Cancer. 2004 Sep 13;91(6):1089-95. doi: 10.1038/sj.bjc.6602092.
92	Diagnosis of clear cell sarcoma by real-time reverse transcriptase-polymerase chain reaction analysis of paraffin embedded tissues: clinicopathologic and molecular analysis of 44 patients from the French sarcoma group.Cancer. 2006 Sep 1;107(5):1055-64. doi: 10.1002/cncr.22099.
93	Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.Pathol Oncol Res. 2019 Jan;25(1):45-50. doi: 10.1007/s12253-017-0324-1. Epub 2017 Sep 29.
94	Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.J Clin Invest. 2019 May 1;129(5):1940-1945. doi: 10.1172/JCI123089. Epub 2019 Mar 5.
95	Glypican 6 is a putative biomarker for metastatic progression of cutaneous melanoma.PLoS One. 2019 Jun 14;14(6):e0218067. doi: 10.1371/journal.pone.0218067. eCollection 2019.
96	Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.J Cancer Res Ther. 2018 Oct-Dec;14(6):1167-1175. doi: 10.4103/jcrt.JCRT_1290_16.
97	Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAF(V600E) inhibitors.Mol Carcinog. 2018 May;57(5):678-683. doi: 10.1002/mc.22786. Epub 2018 Feb 5.
98	Interleukin 4-Induced Gene 1 as an Emerging Regulator of B-Cell Biology and its Role in Cutaneous Melanoma.Crit Rev Immunol. 2019;39(1):39-57. doi: 10.1615/CritRevImmunol.2019030020.
99	Transcriptional regulation of KiSS-1 gene expression in metastatic melanoma by specificity protein-1 and its coactivator DRIP-130.Oncogene. 2007 Mar 15;26(12):1739-47. doi: 10.1038/sj.onc.1209963. Epub 2006 Sep 11.
100	Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas.Oncoimmunology. 2019 Sep 6;8(11):e1660121. doi: 10.1080/2162402X.2019.1660121. eCollection 2019.
101	Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.Clin Cancer Res. 2018 Sep 1;24(17):4119-4125. doi: 10.1158/1078-0432.CCR-18-0791. Epub 2018 May 18.
102	PHLDA1 (pleckstrin homology-like domain, family A, member 1) knockdown promotes migration and invasion of MCF10A breast epithelial cells.Cell Adh Migr. 2018 Jan 2;12(1):37-46. doi: 10.1080/19336918.2017.1313382. Epub 2017 Jun 29.
103	Coexpression network analysis identified that plakophilin 1 is associated with the metastasis in human melanoma.Biomed Pharmacother. 2019 Mar;111:1234-1242. doi: 10.1016/j.biopha.2018.12.135. Epub 2019 Jan 15.
104	Plexin C1, a receptor for semaphorin 7a, inactivates cofilin and is a potential tumor suppressor for melanoma progression.J Invest Dermatol. 2009 Apr;129(4):954-63. doi: 10.1038/jid.2008.329. Epub 2008 Nov 6.
105	Mechanism for Regulation of Melanoma Cell Death via Activation of Thermo-TRPV4 and TRPV2.J Oncol. 2019 Feb 7;2019:7362875. doi: 10.1155/2019/7362875. eCollection 2019.
106	Cellular and molecular evidence for malignancy-inhibitory functions of p15RS.Cell Cycle. 2012 May 15;11(10):1988-98. doi: 10.4161/cc.20400. Epub 2012 May 15.
107	Metastatic melanoma with dedifferentiation and extensive rhabdomyosarcomatous heterologous component.J Cutan Pathol. 2018 May;45(5):360-364. doi: 10.1111/cup.13122. Epub 2018 Mar 1.
108	S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells.Cells. 2019 Jul 20;8(7):755. doi: 10.3390/cells8070755.
109	Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression.Am J Pathol. 2008 Dec;173(6):1873-81. doi: 10.2353/ajpath.2008.080136. Epub 2008 Oct 30.
110	SOX10 Immunostaining in granulomatous dermatoses and benign reactive lymph nodes.J Cutan Pathol. 2019 Aug;46(8):586-590. doi: 10.1111/cup.13470. Epub 2019 May 14.
111	LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.Cancer Cell. 2012 Jun 12;21(6):751-64. doi: 10.1016/j.ccr.2012.03.048.
112	Expression of novel cancer/testis antigen TMEM31 increases during metastatic melanoma progression.Oncol Lett. 2017 Apr;13(4):2269-2273. doi: 10.3892/ol.2017.5728. Epub 2017 Feb 13.
113	PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.Oncogene. 2018 Apr;37(17):2225-2236. doi: 10.1038/s41388-017-0061-7. Epub 2018 Feb 2.